Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 77-83

  Matsudaira, Hiroshi ^a   Asakura, Tadashi ^a   Aoki, Katsuhiko ^a   Searashi, Yasuyuki ^a   Matsuura, Tomokazu ^a   Nakajima, Hisato ^a   Tajiri, Hisao ^a   Ohkawa, Kiyoshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD147 (Emmprin); Immuno liposome; Target chemotherapy

Indexed keywords

CD147 ANTIGEN; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE DOCORUBICIN CONJUGATE; LIPOSOME; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; BREAST; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOMA CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SPECIFICITY; DRUG TARGETING; ENCAPSULATION; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY PARENCHYMA; LIPOSOMAL DELIVERY; PRIORITY JOURNAL; PROSTATE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; LIPOSOMES; MICE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 74549170669     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000477     Document Type: Article

References (30)

1. Trial PA, King HD and DubowchiK DM: Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 52: 328-337, 2003.
2. Anderson DR, Grillo-López A, Varns C, Chambers KS and Hanna N: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25: 705-708, 1997.
3. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T and Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997.
4. Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J and Levy R: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274, 1997.
5. Witziq TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E and Grillo-López AJ: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17: 3793-3803, 1999.
6. Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ and Goldenberg DM: Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 9: 6567-6571, 2003.
7. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
8. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G and Moses MA: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 97: 3884-3889, 2000.
9. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744, 2000.
10. Yan L, Zucker S and Toole BP: Roles of multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93: 199-204, 2005.
11. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P and Yan L: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endo-thelial cell growth factor and matrix metalloproteinases. Cancer Res 65: 3193-3199, 2005.
12. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G and Pantel K: High incidence of EMMPRIN expression in human tumors. Int J Cancer 119: 1800-1810, 2006.
13. Yamada K, Ohkawa K and Joh K: Monoclonal antibody, Mab 12C3, is a sensitive immunohistochemical marker of early malignant change in epithelial ovarian tumors. Am J Clin Pathol 103: 288-294, 1995.
14. Ishibashi Y, Matsumoto T, Niwa M, Suzuki Y, Omura N, Hanyu N, Nakada K, Yanaga K, Yamada K, Ohkawa K, Kawakami M and Urashima M: CD147 and matrix metallo-proteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 101: 1994-2000, 2004.
15. Takahashi N, Asakura T and Ohkawa K: Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells. Anti-Cancer Drugs 7: 687-696, 1996.
16. Asakura T, Takahashi N, Takada K, Inoue T and Ohkawa K: Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells. Anti-Cancer Drugs 8: 199-203, 1997.
17. Asakura T, Sawai T, Hashidume Y, Ohkawa Y, Yokoyama S and Ohkawa K: Caspase-3 activation during doxorubicin conjugated with glutathione-mediated apoptosis. Br J Cancer 80: 711-715, 1999.
18. Asakura T, Ohkawa K, Takahashi N, Takada K, Inoue T and Yokoyama S: Glutathione-doxorubicin conjugate expresses potent cytotoxicity by a suppression of glutathione S-transferase activity: Comparison between doxorubicin-sensitive and-resistant rat hepatoma cells. Br J Cancer 76: 1333-1337, 1997.
19. Asakura T, Hashizume Y, Tashiro K, Searashi Y, Ohkawa K, Nishihira J, Sakai M and Shibasaki T: Suppression of GST-P by treatment with glutathione-doxorubicin conjugate induces potent apoptosis in rat hepatoma cells. Int J Cancer 94: 171-177, 2001.
20. De Castro R, Zhang Y, Guo H, Kataoka H, Gordon MK, Toole B and Biswas G: Human keratinocytes express EMMPRIN, an extracellular matrix metalloproteinase inducer. J Invest Dermatol 106: 1260-1265, 1996.
21. Chen X, Kanekura T and Kanzaki T: Expression of Basigin in human fetal, infantile and adult skin and in basal cell carcinoma. J Cutan Pathol 28: 184-190, 2001.
22. Chen X, Kanekura T, Tsuyama S, Murata F and Kanzaki T: Ultrastructural localization of basigin in normal human epidermis. Histochem Cell Biol 115: 465-470, 2001.
23. Kuno N, Kadomatsu K, Fan QW, Hagihara M, Senda T, Mizutani S and Muramatsu T: Female sterility in mice lacking the basigin gene, which encodes a transmembrane glycoprotein belonging to the immunoglobulin superfamily. FEBS Lett 425: 191-194, 1998.
24. Koch C, Staffler G, Huttinger R, Hilgert I, Prager E, Cerny J, Steinlein P, Majdic O, Horejsí V and Stockinger H: T cell activation-associated epitopes of CD147 in regulation of T cell response, and their definition by antibody affinity and antigen density. Int Immunol 11: 777-786, 1999.
25. Kirsch AH, Diaz LA Jr, Bonish B, Antony PA and Fox DA: The pattern of expression of CD147/neurothelin during human T-cell ontogeny as defined by the monoclonal antibody 8D6. Tissue Antigens 50: 147-152, 1997.
26. Zhu P, Ding J, Zhon J, Dong WJ, Fan CM and Chen ZN: Expression of CD147 on monocytes/macrophages in rheumatoid arthritis: its potential role in monocyte accumulation and matrix metalloproteinase production. Arthritis Res Ther 7: R1023-R1033, 2005.
27. Coker ML, Doscher MA, Thomas CV, Galis ZS and Spinale FG: Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 277: H777-H787, 1999.
28. Sameshima T, Nabeshima K, Toole BP, Inoue T, Yokogami K, Nakano S, Ohi T and Wakisaka S: Correlation of emmprin expression in vascular endothelial cells with blood-brain-barrier function: a study using magnetic resonance imaging enhanced by Gd-DTPA and immunohistochemistry in brain tumors. Virchows Arch 442: 577-584, 2003.
29. Coste I, Gauchat JF, Wilson A, Izui S, Jeannin P, Delneste Y, MacDonald HR, Bonnefoy JY and Renno T: Unavailability of CD147 leads to selective erythrocyte trapping in the spleen. Blood 97: 3984-3988, 2001.
30. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, Watsky MA, De Wever B, Calvo F, Mauviel A and Menashi S: Differential expression of extracellular metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epitheliostromal interactions and matrix metalloproteinase induction. Am J Pathol 166: 209-219, 2005.